Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular EdemaGlobeNewsWire • 02/27/23
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 02/15/23
3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall StreetThe Motley Fool • 01/23/23
Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic responseMarket Watch • 01/09/23
Ocugen stock up 16% premarket after company announced positive results for its COVID vaccineMarket Watch • 01/09/23
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints MetGlobeNewsWire • 01/09/23
Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital AmaurosisGlobeNewsWire • 12/15/22
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital AmaurosisGlobeNewsWire • 12/07/22